Targeting ALK rearrangements in NSCLC: current state of the art
L Peng, L Zhu, Y Sun, J Stebbing, G Selvaggi… - Frontiers in …, 2022 - frontiersin.org
Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can
be effectively treated with a variety of ALK-targeted drugs. After the approval of the first …
be effectively treated with a variety of ALK-targeted drugs. After the approval of the first …
[HTML][HTML] Testing modalities for ALK-driven lung cancer: A narrative review
S Nathany, M Sharma, U Batra - Cancer Research, Statistics, and …, 2023 - journals.lww.com
Anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC)
comprises a distinct molecular entity with a reported global prevalence of 5–7%. The …
comprises a distinct molecular entity with a reported global prevalence of 5–7%. The …
[HTML][HTML] Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences
F Tabbò, LA Muscarella, E Gobbini, D Trombetta… - European Journal of …, 2022 - Elsevier
Introduction Anaplastic lymphoma kinase (ALK) fusions identify a limited subset of non–
small cell lung cancer (NSCLC) patients, whose therapeutic approach have been radically …
small cell lung cancer (NSCLC) patients, whose therapeutic approach have been radically …
[HTML][HTML] ALK-driven NSCLC: A narrative review-Part I
S Nathany, M Sharma, U Batra - Cancer Research, Statistics, and …, 2023 - journals.lww.com
Anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is a
molecularly distinct subgroup of oncogene-addicted NSCLC, accounting for 3-5% of cases …
molecularly distinct subgroup of oncogene-addicted NSCLC, accounting for 3-5% of cases …
The Impact of the ALK Fusion variant on Clinical Outcomes in EML4-ALK Patients with NSCLC: a Systematic Review and Meta-Analysis
S Wang, R Luo, Y Shi, X Han - Future Oncology, 2022 - Taylor & Francis
Background: Recent studies showed that ALK-fusion variants are associated with
heterogeneous clinical outcomes. However, contradictory conclusions have been drawn in …
heterogeneous clinical outcomes. However, contradictory conclusions have been drawn in …
A poor prognostic ALK phenotype: A review of molecular markers of poor prognosis in ALK re-arranged non-small cell lung cancer
SWS Chan, J Zeng, J Young, SH Barghout… - Clinical Lung Cancer, 2024 - Elsevier
Background Patients with non-small cell lung cancer with anaplastic lymphoma kinase
(ALK) rearrangements derive a significant and durable clinical benefit from tyrosine kinase …
(ALK) rearrangements derive a significant and durable clinical benefit from tyrosine kinase …
[HTML][HTML] Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study
C Kamali, G Tsakonas, P Hydbring… - Translational Lung …, 2024 - pmc.ncbi.nlm.nih.gov
Background Rearrangement in anaplastic lymphoma kinase (ALK) occurs in 4–7% of non-
small cell lung cancer (NSCLC) cases. Despite improved survival with tyrosine kinase …
small cell lung cancer (NSCLC) cases. Despite improved survival with tyrosine kinase …